Induction with anti-T-lymphocyte globulins and human immunoglobulins: A strategy for hyperimmunized liver transplant patients

doi:10.4254/wjh.v18.i3.115221

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(28)

(25)

(0)

(8)

(1)

(564)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 115221
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115221

Table 3 Biopsy-proven rejection, n (%)/mean ± SD

	High-risk group (n = 46)	Low-risk group (n = 46)	P value
Overall rejection	13 (28.3)	12 (26.1)	0.82
Overall time to rejection (months)	3.3 ± 6.7	3.4 ± 6.9	0.98
Median IQR (Q1-Q3)	0.367 (0.3-3.1)	0.45 (0.2-4.3)	0.98
Rejection type			0.21
TCMR	9 (19.6)	12 (26.1)
aAMR	2 (4.3)	0 (0)
aAMR + TCMR	2 (4.3)	0 (0)
TCMR
BANFF classification			0.21
Mild (4-5)	7/11 (63.6)	10/12 (83.3)
Moderate (6-7)	4/11 (36.4)	2/12 (16.7)
Severe (8-9)	0 (0)	0 (0)
Median time to TCMR (Q3-Q1) (days)	7.9 (96.9-8)	13.5 (129-4.8)	0.87
Treatment of TCMR (n = 9)			0.14
Steroid bolus	5/46 (10.9)	4/46 (8.7)
Increase CNI dose	1/46 (2.2)	2/46 (4.3)
Spontaneously resolved	3/46 (6.5)	6/46 (13.0)
aAMR
aAMR	4/46 (8.6)	0 (0)	0.06
Median time to aAMR (Q3-Q1) (days)	36 (81.8-10.5)	-	-
Treatment of aAMR
Switch cyclosporine to tacrolimus	1/4 (25.0)	-	-
Steroid bolus + rituximab + 5 sessions PE	1/4 (25.0)	-	-
Steroid bolus + IVIG	2/4 (50.0)	-	-

High SD is due to presence of outliers. aAMR: Acute antibody-mediated rejection; TCMR: Acute T-cell rejection; CNI: Calcineurin inhibitors; IQR: Interquartile range; IVIG: Intravenous immunoglobulin; PE: Plasma exchange.

Full Size Table

Citation: EL-Domiaty N, Coilly A, Sebagh M, Taupin JL, Ibrahim W, Sacleux SC, Ichai P, Duhaut L, Pittau G, Ciacio O, Salloum C, Sa-Cunha A, Azoulay D, Feray C, Cherqui D, Shiha G, Samuel D, Saliba F. Induction with anti-T-lymphocyte globulins and human immunoglobulins: A strategy for hyperimmunized liver transplant patients. World J Hepatol 2026; 18(3): 115221
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/115221.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.115221

EL-Domiaty N, Coilly A, Sebagh M, Taupin JL, Ibrahim W, Sacleux SC, Ichai P, Duhaut L, Pittau G, Ciacio O, Salloum C, Sa-Cunha A, Azoulay D, Feray C, Cherqui D, Shiha G, Samuel D, Saliba F. Induction with anti-T-lymphocyte globulins and human immunoglobulins: A strategy for hyperimmunized liver transplant patients. World J Hepatol 2026; 18(3): 115221 [DOI: 10.4254/wjh.v18.i3.115221]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.